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Abstract Heat shock proteins (hsps) are protective against
the harmful effects of mutant expanded polyglutamine repeat
proteins that occur in diseases such as Huntington’s, prompt-
ingthesearchforpharmacologiccompoundsthatincreasehsp
expression in cells as potential treatments for this and related
diseases. In this paper, we show that celastrol, a compound
recently shown to up-regulate hsp gene expression, signifi-
cantly decreases killing of cells expressing mutant polyglu-
tamine protein. This effect requires the presence of the
transcription factor responsible for mediating inducible hsp
gene expression, HSF1, and is correlated with decreased
amounts and increased sodium dodecyl sulfate (SDS)
solubility of polyglutamine aggregates. These results suggest
thepotentialofcelastrolasatherapeuticagentinthetreatment
of human polyglutamine expansion diseases.
Keywords Celastrol.HSF1.Polyglutamine.Aggregates.
Heatshockproteins.hsp70
Introduction
A large number of neurodegenerative diseases, including
Huntington’s and Kennedy’s diseases, are characterized by
expanded polyglutaminerepeatsin certain proteins leading to
their aggregation and toxic effects on the cells expressing
them [1, 2]. A number of results suggest that polyglutamine-
containing aggregates are important both for the initiation
and progression of these diseases [3, 4]. Polyglutamine
protein aggregates in brains of patients and transgenic
animals have been found to contain various molecular
chaperones, ubiquitin, and components of the 20S protea-
some [5, 6]. This suggests that neuronal cells recognize the
protein aggregates as abnormally folded and try to disag-
gregate or degrade the mutant proteins by recruiting
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immunology.chaperones and proteasomal components [7]. Consistent
with this view, increased expression of hsp70 and other heat
shock proteins (hsps) has been found to be effective in
reducing the toxicity of mutant polyglutamine proteins,
suggesting the potential of pharmacological up-regulation of
hsp gene regulation as a means for treating polyglutamine
expansion diseases such as Huntington’s[ 8–11].
Heat Shock Factor 1, HSF1, is the transcription factor
responsible for up-regulating the expression of hsp70 and
other hsp genes in response to cellular stress [12, 13]. HSF
activation involves stress-induced conversion of this factor
to its trimeric DNA-binding form [14–17]. The activated
trimeric HSF1 then binds to heat shock elements in the
promoters of hsp genes to up-regulate their transcription,
ultimately leading to elevated levels of cytoprotective hsps
in these cells.
The function of HSF1 as a key positive regulator of hsp
expression, coupled to the observed ability of hsp proteins to
protect cells from polyglutamine toxicity prompted the
hypothesis that interventions that lead to activation of HSF1
could provide protection for cells against this toxicity and
possibly represent agents that could be useful in treating
polyglutamine expansion diseases such as Huntington’s[ 10,
18]. Consistent with this hypothesis, expression in cells of a
constitutively active mutant HSF1 protein results in de-
creased polyglutamine toxicity and aggregate formation in
both cell culture and animal models [19, 20]. These and
other results have stimulated the search for pharmacological
compounds capable of up-regulating hsp gene expression, as
such compounds would theoretically have potential as
treatments for these and other diseases of protein misfolding.
Recently, it was demonstrated that a compound called
celastrol, which is found in the Celastraceae family of plants
and is already being used to treat diseases such as rheumatoid
arthritis, bacterial infection, and fever [21, 22], is able to
activate HSF1 and up-regulate hsp gene expression [18].
Celastrol has previously been found to inhibit the aggrega-
tion of purified Q58-huntingtin 1-171 amino terminal
fragment in an in vitro assay, although this study did not
examine effects of celastrol on polyglutamine aggregation in
cells [23]. Celastrol has also been found to inhibit the
cytotoxicity of expanded polyglutamine form of huntingtin
exon 1 [24] and androgen receptor [25], but these studies did
not examine the mechanism by which celastrol protects cells
from expanded polyglutamine protein cytotoxicity.
The results of the experiments presented in this paper
demonstrate that celastrol is effective in preventing both the
aggregation and toxicity of polyglutamine expression in
cells and that it mediates these effects via the HSF1-
mediated gene expression pathway. These results support
the potential of this drug as a possible therapeutic agent for
treating polyglutamine expansion diseases. The results also
suggest that other drugs that stimulate HSF1 activity
leading to hsp gene expression may also have beneficial
activity against these disease states as well as other human
diseases that are caused by protein misfolding.
Materials and methods
Plasmids, cell culture, and celastrol
Theexpressionconstructs encodingQ19-YFP,Q57-YFP,and
Q81-YFP were kindly provided by Dr. James Burke (Duke
University). The polyglutamine-YFP (Qn-YFP) vectors were
constructed using CAG repeats that were synthesized by
polymerase chain reaction (PCR) from human dentatorubral
pallidoluysian atrophy (DRPLA) cDNAs containing differ-
ent CAG repeats. HeLa cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Cellgro) supplemented
with 10% fetal bovine serum (FBS) and 50 μg/ml
gentamicin. PC12 cells were cultured in DMEM medium
(Cellgro) supplemented with 5% FBS and 10% heat-
inactivated horse serum (Gibco), and 100 units/ml Penicillin-
Streptomycin (Gibco). HSF1+/+ and HSF1−/− mouse embryo
fibroblast (MEF) cells (kindly provided by Dr. Ivor Benjamin,
University of Utah) were cultured in DMEM medium
(Cellgro) supplemented with 10% FBS, 1× Penicillin-
streptomycin (Gibco), and 1× Non-essential amino acids
(Gibco). Transfection was performed using Effectene
transfection reagent (Qiagen), following the manufacturer’s
protocol. Celastrol (Calbiochem) was dissolved in dimethyl
sulphoxide at a stock concentration of 5.54 mM.
Trypan blue cell viability assay
Cellswerecollectedbycentrifugationat1,000rpmfor10min
at 4°C, and the pellet was washed twice with 1× phosphate-
buffered saline (PBS).The cellpellet was then resuspended in
1× PBS to a concentration of approximately 10
6 cells/ml. A
1:1 dilution of the suspension was prepared using a solution
containing 0.4% trypan blue stain (Gibco), and the suspen-
sion was then loaded into the counting chamber of a
hemocytometer. The number of stained cells as well as the
total number of cells was counted, and the percentage of
stained cells was taken to represent the percentage of cell
death. Experiments were repeated three times.
Fluorescence microscopy
Cells were seeded on coverslips, and 48 h after transfection,
Hoechst 33342 and verapamil were added to the medium to
final concentrations of 5 and 50 μg/ml, respectively. After
incubation at 37°C for 30 min, the medium was removed,
and the coverslips washed with 1× PBS for 5 min. A
solution containing 3.7% paraformaldehyde in 1× PBS was
1422 J Mol Med (2007) 85:1421–1428added, and after 20 min incubation at room temperature,
coverslips were washed with 1× PBS for 5 min. Coverslips
were washed briefly three times in distilled water and
mounted onto a slide spotted with 15 μl Vectashield (Vector
Laboratories). Excess fluid was wicked from the coverslip
and the edges of the coverslip sealed with fingernail polish.
The fluorescence was then visualized using a Nikon
fluorescent microscope and pictures taken with a Nikon
Spotcam digital-imaging camera. To quantify the formation
of polyglutamine aggregates, visual fields which contained
similar numbers of cells (based on the density of nuclei
stained by Hoechst) were chosen under 20× objective, and
then the number of cells that contained aggregates in each
field of vision was counted. Three different visual fields
were quantified in each case. There were approximately
300 cells in each visual field for the experiments involving
HeLa cells and PC12 cells, and approximately 100 cells in
the experiments involving MEF cells. We scored a cell as
positive if it had any visible aggregates, and the aggregates
in the majority of cells appeared to be intranuclear or
perinuclear (example shown in Fig. S1).
Extract preparation and Western blot assay
Cell lysis was performed on ice for 30 min in 50 mM Tris–
HCl [pH 8.0], 100 mM NaCl, 5 mM MgCl2, 0.5% NP40
lysis buffer [26] containing 1× protease inhibitor cocktail
(Roche), and 1 mM phenylmethanesulfonyl fluoride added.
To examine hsp70 level, the cell lysate was cleared by
centrifugation at 1,000 rpm at 4°C for 10 min, and the
protein concentration of the supernatant was then deter-
mined by BioRad assay. Five micrograms of protein extract
was subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and Western blot follow-
ing standard procedures. The antibodies and dilutions used
to probe the Western blots were as follows. Anti-hsp70
(stress-induced form; Stressgen) was used at 1:10,000, anti-
β-actin antibody (Sigma) was used at 1:10,000, and the
anti-green fluorescent protein (GFP) polyclonal antibody
(Bethyl labs) was used at a dilution of 1:4,000. Hsp70
Western blots were quantified using ImageQuant software.
Filtration assay
Cell lysis was performed on ice for 30 min in the lysis
buffer described above. The insoluble fraction was obtained
by centrifugation of the cell lysate at 14,000 rpm at 4°C for
10 min. The pellet was resuspended in DNase buffer
(20 mM Tris–HCl [pH 8.0], 15 mM MgCl2, and 0.5 mg/ml
DNase I), followed by incubation at 37°C for 1 h. After
DNase treatment, the protein concentration was determined
by analyzing an aliquot using the BioRad assay. The
incubation was terminated by adjusting the mixtures to
20 mM ethylenediamine tetraacetic acid (EDTA), 2%
sodium dodecyl sulfate (SDS), and 50 mM dithiothreitol
and boiling for 5 min. Thirty micrograms of protein was
diluted into 200 μl 2% SDS, and this was then filtered
through a 0.2-μm pore size cellulose acetate membrane
(Schleicher & Schuell) that was equilibrated with 2% SDS
using a Dot-Blot system (Schleicher & Schuell). Filters
were washed twice with 200 μl 0.1% SDS and then
subjected to anti-GFP Western blot [27].
SDS solubility assay
To perform the SDS solubility assay, cell lysates were
prepared as described above for the filtration assay,
including the 14,000 rpm centrifugation of the cell lysate
and DNase treatment and protein concentration determina-
tion by BioRad assay. Forty micrograms of protein was
then adjusted to 2× SDS-PAGE sample buffer (62.5 mM
Tris·HCl [pH 6.8], 10% glycerol, 2% SDS, 5% β-
mercaptoethanol) and boiled for 5 min after which the
sample was analyzed by SDS-PAGE and Western blot with
anti-GFP polyclonal antibody.
Statistical analysis
Statistical significance was determined using the Student’s t
test. A P value of <0.05 was considered to be statistically
significant.
Results
Celastrol protects against polyglutamine toxicity
The experimental system we chose to test for effects of
celastrol on polyglutamine aggregation and toxicity is
transfection of a Q57-YFP fusion protein into cell lines
(gift of Dr. James Burke), which is an established model for
the aggregation of polyglutamine containing proteins in
vivo [28]. Consistent with this, the Q57-YFP protein forms
clearly visible aggregates upon expression in HeLa cells,
while cells transfected with Q19-YFP exhibit a diffuse
pattern (Fig. S1). A previous study showed that 8 h of
celastrol treatment leads to increased levels of the hsp70
protein [18]. As the studies described in this paper include
cell death and aggregation assays performed at 48 h after
transfection with the Q57-YFP construct, we wanted to
ensure that cells treated with celastrol treatment for longer
times also exhibit elevated hsp70 expression. As shown in
Fig. 1a (upper panel), celastrol treatment of HeLa cells for
24 or 48 h both result in a dose-dependent increase in
expression of the hsp70 protein. Quantification of these
hsp70 Western blot results indicates that the induction of
J Mol Med (2007) 85:1421–1428 1423hsp70 by each celastrol concentration is very similar at 24
and 48 h, showing that treatment with this drug results in a
sustained increase in hsp70 levels (lower panel). Next, to
test whether treatment with this drug confers protection
from polyglutamine toxicity, HeLa cells were transfected
with the Q57-YFP construct and then incubated in media
containing different concentrations of celastrol. The results
of this experiment, shown in Fig. 1b, reveal that celastrol
treatment is associated with a significant decrease in death
of these cells expressing this mutant polyglutamine protein.
Celastrol protective effect are correlated with decreased
number of cells containing polyglutamine aggregates
To determine whether the ability of celastrol to protect cells
from polyQ toxicity could be mediated via effects on polyQ
aggregates, we then examined whether celastrol treatment
alters the number of polyQ aggregates in cells and/or their
solubility. The results of these experiments show that
treatment with celastrol is associated both with a decrease
in the number of cells containing Q57-YFP aggregates, as
quantified by fluorescence microscopy (Fig. 2a), and also
with an increase in the amount of Q57-YFP that can be
solubilized from aggregates by SDS treatment (Fig. 2b).
SDS solubility of aggregates is related with their toxicity,
and data from previous studies suggests that molecular
chaperones may ameliorate the neurodegenerative effect of
mutant polyglutamine protein, at least in part, by increasing
the solubility of these proteins [9, 29]. Together, the results
shown in Figs. 1 and 2 indicate that celastrol treatment
decreases the death of cells expressing mutant polyglu-
tamine protein and also decreases the number of cells
containing Q57-YFP-aggregates and the insolubility of
Q57-YFP-aggregates.
Protective effects of celastrol treatment in PC12 cells
As the deleterious effects of expression of mutant polyglu-
tamine proteins in vivo are observed primarily in cells of
neuronal origin, we next sought to test the effect of celastrol
treatment on polyglutamine toxicity and aggregation in
PC12 cells. As shown in Fig. 3a, PC12 cells are very
sensitive to killing by expression of the Q57-YFP protein,
but as observed for HeLa cells in Fig. 1b above, celastrol
treatment results in a significant decrease in death of these
cells. As was observed in the experiments using HeLa cells,
treatment of PC12 cells with celastrol resulted in a
significant decrease in the number of polyglutamine
aggregates in the cells (Fig. 3b) and an increase in the
amount of Q57-YFP that can be solubilized from aggre-
gates by SDS treatment (Fig. 3c). Interestingly, the
concentrations of celastrol required to achieve these effects
on polyglutamine toxicity and number and solubility
properties of aggregates in PC12 cells were significantly
lower than that needed for HeLa cells.
HSF1−/− cells exhibit increased polyglutamine aggregation
and toxicity
Inducible hsp expression is thought to be important for the
ability of cells to decrease polyglutamine toxicity and
Fig. 1 CelastroltreatmentreducesQ57-YFPcytotoxicity.a Hsp70 protein
level is increased by celastrol treatment. HeLa cells were treated with the
indicated concentrations of celastrol for 24 or 48 h, after which cell
extracts were made and subjected to Western blot using antibodies against
hsp70 or β-actin (upper panel). These results were quantified using the
ImageQuant program, and the values for the two treatment times, grouped
by celastrol concentration, were graphed (lower panel). b HeLa cells were
transfected with Q57-YFP along with celastrol treatment at the concen-
trations indicated. After 48 h, the amount of cell death was determined by
trypan blue assay. Data are shown as means ± SE (*P<0.007, **P<0.004,
***P<0.0001, for each celastrol concentration treatment vs no celastrol)
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HSF1−/− MEFs [30] that are transfected with Q57-YFP
exhibit a higher incidence of cell death than HSF1+/+ MEF
cells (Fig. 4a). The HSF1−/− MEFs also show increased
Q57-YFP aggregation, both as measured by numbers of
aggregates using fluorescence microscopy of cells (Fig. 4b)
and by amount of aggregated Q57-YFP protein present in
cell extracts detected by filtration assay (Fig. 4c).
Protective effects of celastrol require HSF1
Based on previous results showing the ability of celastrol to
activate HSF1 leading to increased hsp gene expression
[18], we hypothesized that this drug’s ability to decrease
polyglutamine toxicity and aggregation shown by the
Fig. 3 Celastrol effects on Q57-YFP toxicity and aggregates in PC12
cells. PC12 cells were transfected with Q57-YFP along with celastrol
treatment at the concentrations indicated. After 48 h, the amount of cell
death was determined by trypan blue assay (a), the number of cells
containing Q57-YFP aggregates was quantified using fluorescence
microscopy (b), and the amount of Q57-YFP monomer solubilized from
aggregates by SDS treatment visualized by Western blot using anti-GFP
antibody (c). In a and b, data are shown as means ± SE [*P<0.0001
and **P<0.0001 (a), *P<0.001 and **P<0.0001 (b), in each case for
each celastrol concentration treatment vs no celastrol)
Fig. 2 Celastrol treatment reduces number of cells containing Q57-
YFP aggregates and increases Q57-YFP solubility. HeLa cells were
transfected with Q57-YFP along with celastrol treatment at the
concentrations indicated. a After 48 h of transfection, the formation
of Q57-YFP aggregates was quantified using fluorescence microsco-
py. Visual fields which contained similar numbers of cells (based on
the density of nuclei stained by Hoechst) were chosen under 20×
objective, and then the number of aggregates in each field of vision
was counted. Three different visual fields were quantified in each
case, and data are shown as means ± SE (*P<0.004, **P<0.001,
***P<0.0003, for each celastrol concentration treatment vs no
celastrol). b To determine the amount of Q57-YFP monomer that
could be solubilized from aggregates in lysates of the transfected cells
by SDS treatment, the protein concentration of the insoluble fraction
of the cell lysates was determined, and then 40 μg of protein was
subjected to SDS solubilization treatment, followed by Western blot
using anti-GFP antibody
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HSF1-regulated gene expression pathway. To test this
hypothesis, we compared the effect of celastrol treatment
on polyglutamine toxicity and aggregation in the HSF1+/+
vs HSF1−/− MEF cells. Celastrol does not exhibit any
toxicity in HeLa cells at 1.6 μM, but we found its optimal
concentration in MEF cells to be lower than that of HeLa
cells. Thus, for these experiments, we used 0.4 μM
celastrol treatment, which has no toxic effect in either
HSF1−/− or wild-type MEFs (data not shown). First,
Western blot analysis shows that the HSF1−/− cells are
unable to up-regulate hsp70 protein expression in response
to celastrol treatment, demonstrating that celastrol-induced
up-regulation of hsp70 expression is mediated by the
HSF1-regulated gene expression pathway (Fig. 5a).
The results shown above (Figs. 1, 2, 3,a n d5a) indicatethat
celastrol treatment is effective in preventing polyglutamine
aggregation and toxicity and that this drug up-regulates hsp70
expression by an HSF1-dependent mechanism. These results
suggest that celastrol treatment protects cells by stimulating
HSF1-dependent expression of hsps. However, celastrol
could also modulate other cellular activities that could
contribute to these protective effects. Thus, to test the
contribution of HSF1-regulated pathways in these protective
effects, we transfected HSF1+/+ and HSF1−/− MEF cells
with Q57-YFP in combination with celastrol treatment and
then measured the amount of cell death and levels of
aggregated Q57-YFP. The results of this experiment show
that, as it did for the HeLa and PC12 cells in the experiments
of Figs. 1 and 3 above, celastrol treatment resulted in
decreased death of HSF1+/+ MEF cells transfected with
Q57-YFP, but treatment with this drug did not protect the
HSF1−/− cells (Fig. 5b). Consistent with these results, the
HSF1+/+ cells, but not the HSF1−/− cells, showed decreased
levels of aggregated Q57-YFP upon celastrol treatment, as
measured by the filtration assay (Fig. 5c). These results
suggest that the HSF1 protein plays an important role in the
protective effects of celastrol against polyglutamine toxicity
and aggregation.
Discussion
The results described above indicate that the drug celastrol
is able to decrease polyglutamine toxicity, supporting the
proposal that this drug could potentially be useful in the
treatment of Huntington’s disease and possibly other human
polyglutamine expansion disorders. In support of this
possibility, it has been found that celastrol treatment of
mice results in elevation of hsp70 levels in neurons in the
brains of these mice [31]. The results also show that lower
concentrations of celastrol are required for its protective
effects against polyglutamine toxicity in PC12 cells, cells
Fig. 4 HSF1−/− cells exhibit higher Q57-YFP aggregation and cell
death. HSF1−/− and wild-type MEF cells were transfected with Q57-
YFP, and after 48 h, cell death was examined by trypan blue assay (a),
and the number of cells containing Q57-YFP aggregates was
quantified using fluorescence microscopy (b), or filtration assay, in
which 30 μg of the insoluble fraction was filtered through 0.2 μm
cellulose acetate membrane, and the aggregates retained on the
membrane were immunoblotted using anti-GFP antibody (c). In a
and b, data are shown as means ± SE. *P<0.008 (a); *P<0.003 (b)
1426 J Mol Med (2007) 85:1421–1428with neuronal characteristics, compared to other cell types.
A particularly beneficial aspect of this drug is that it is
already being used to treat people with other disorders [21,
22], and thus it could likely be adapted more quickly for
use in treating polyglutamine expansion diseases than other
drugs not currently being used in humans.
Results presented in this paper indicate that the protec-
tive effect of celastrol against polyglutamine toxicity is
associated with decreased numbers of cells containing
aggregates as well as increased SDS-solubility of the
mutant polyglutamine protein. This might seem to be at
odds with findings that formation of polyglutamine aggre-
gates can be protective for cells expressing these mutant
proteins [32–34]. However, our results are consistent with
the findings of a number of studies which indicate that
molecular chaperones can reduce the formation of polyglu-
tamine aggregates and increase the solubility of expanded
polyglutamine proteins [8–11, 19, 20]. While one study
found that hsp40 overexpression, but not hsp70 over-
expression, was associated with reduced aggregation [35],
the results of a number of studies do suggest that chap-
erones are able to reduce aggregation of mutant polyglu-
tamine proteins. Molecular chaperones could be acting at
multiple levels to reduce polyglutamine toxicity, but one
possibility that has been proposed is that these chaperones,
and by extension celastrol through its HSF1-mediated up-
regulation of chaperones, may be acting at an early step to
prevent formation of toxic intermediates before they can
become part of larger aggregates [8–11, 19, 20]. This would
explain both how celastrol treatment protects cells from
polyglutamine toxicity and the effects we observe on
polyglutamine aggregates in the celastrol-treated cells. An
alternative explanation that must be considered, in keeping
with previous studies indicating that aggregate formation
can be protective for cells [32–34], is that the results we
observe relating celastrol with the numbers of cells
containing polyglutamine aggregates could be due, at least
in part, to a potential ability of celastrol to enhance the
survival of cells that do not contain aggregates, which
would then lead to a perceived decrease in the numbers of
cells containing aggregates in our experiments. Our data do
indicate, however, the protective effects of celastrol with
respect to polyglutamine toxicity.
In addition to its ability to its effects on HSF1
activity, celastrol has been found to affect other pathways
in the cell, including the NF–κB pathway [18, 21, 22,
36]. However, our results suggest that the beneficial effects
of celastrol treatment in decreasing polyglutamine toxicity
are mediated through the action of the HSF1-regulated gene
expression pathway, based on the finding that celastrol is
not protective in Q57-YFP transfected HSF1−/− MEF cells
(Fig. 5b). This finding also suggests that other drugs that
activate HSF1 could also have potential as candidate
therapeutic agents for treating polyglutamine expansion
diseases.
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Fig. 5 Celastrol decreases Q57-YFP toxicity and aggregation in wild-
type but not HSF1−/− MEF cells. a Celastrol treatment does not
induce hsp70 expression in HSF1−/− cells. Wild-type and HSF1−/−
MEF cells were treated with no celastrol or 0.4 μM celastrol, and after
12 h, cell extracts were made, and 5 μg protein was loaded into each
lane for immunoblotting with anti-hsp70 antibodies. b and c Wild-
type and HSF1−/− MEF cells were transfected with Q57-YFP, with
celastrol at the indicated concentrations added at the same time. After
48 h, cell death was examined by trypan blue assay (b), with data
shown as means ± SE (*P<0.002 for HSF2+/+ 0.4 μM celastrol vs no
celastrol; *P<0.002 for HSF2−/− 0.4 μM celastrol vs no celastrol),
and amount of aggregated Q57-YFP was determined by filtration
assay followed by anti-GFP Western blot (c)
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